BK Polyomavirus-Associated Nephropathy
- BKPyVAN is a significant cause of kidney transplant complications. With no standardized treatment protocols, immunosuppression reduction remains the cornerstone of management. #TransplantNephrology #BKPyVAN
- BKPyVAN is a significant cause of kidney transplant complications. With no standardized treatment protocols, immunosuppression reduction remains the cornerstone of management. #TransplantNephrology #BKPyVAN
January 12, 2025 at 1:11 PM
BK Polyomavirus-Associated Nephropathy
- BKPyVAN is a significant cause of kidney transplant complications. With no standardized treatment protocols, immunosuppression reduction remains the cornerstone of management. #TransplantNephrology #BKPyVAN
- BKPyVAN is a significant cause of kidney transplant complications. With no standardized treatment protocols, immunosuppression reduction remains the cornerstone of management. #TransplantNephrology #BKPyVAN
new data on potravitug, a drug for bk polyomavirus-associated nephropathy (bkpyvan). this is a tough kidney complication after transplant, with no approved targeted treatments. in a phase 2 trial, 24.
July 4, 2026 at 2:02 AM
new data on potravitug, a drug for bk polyomavirus-associated nephropathy (bkpyvan). this is a tough kidney complication after transplant, with no approved targeted treatments. in a phase 2 trial, 24.
Future directions:
• Understanding BKPyV pathophysiology will aid drug development (e.g., targeting viral replication and immune evasion mechanisms).
• Long-term data on immunosuppression strategies and novel therapies is critical. #BKPyVAN
• Understanding BKPyV pathophysiology will aid drug development (e.g., targeting viral replication and immune evasion mechanisms).
• Long-term data on immunosuppression strategies and novel therapies is critical. #BKPyVAN
January 12, 2025 at 1:11 PM
Future directions:
• Understanding BKPyV pathophysiology will aid drug development (e.g., targeting viral replication and immune evasion mechanisms).
• Long-term data on immunosuppression strategies and novel therapies is critical. #BKPyVAN
• Understanding BKPyV pathophysiology will aid drug development (e.g., targeting viral replication and immune evasion mechanisms).
• Long-term data on immunosuppression strategies and novel therapies is critical. #BKPyVAN
Re-transplantation after BKPyVAN-associated graft loss:
• Pre-transplant DNAemia clearance is ideal but not mandatory.
• Allograft nephrectomy may help but carries sensitization risks.
Guidelines are needed for these complex cases. #KidneyTransplant
• Pre-transplant DNAemia clearance is ideal but not mandatory.
• Allograft nephrectomy may help but carries sensitization risks.
Guidelines are needed for these complex cases. #KidneyTransplant
January 12, 2025 at 1:11 PM
Re-transplantation after BKPyVAN-associated graft loss:
• Pre-transplant DNAemia clearance is ideal but not mandatory.
• Allograft nephrectomy may help but carries sensitization risks.
Guidelines are needed for these complex cases. #KidneyTransplant
• Pre-transplant DNAemia clearance is ideal but not mandatory.
• Allograft nephrectomy may help but carries sensitization risks.
Guidelines are needed for these complex cases. #KidneyTransplant
Key challenges in BKPyVAN care:
• Lack of standardized BKPyV DNAemia thresholds across centers.
• Limited RCTs to define optimal immunosuppression reduction and adjunctive therapies.
Global collaboration is essential to address these gaps. #ClinicalTrials
• Lack of standardized BKPyV DNAemia thresholds across centers.
• Limited RCTs to define optimal immunosuppression reduction and adjunctive therapies.
Global collaboration is essential to address these gaps. #ClinicalTrials
January 12, 2025 at 1:11 PM
Key challenges in BKPyVAN care:
• Lack of standardized BKPyV DNAemia thresholds across centers.
• Limited RCTs to define optimal immunosuppression reduction and adjunctive therapies.
Global collaboration is essential to address these gaps. #ClinicalTrials
• Lack of standardized BKPyV DNAemia thresholds across centers.
• Limited RCTs to define optimal immunosuppression reduction and adjunctive therapies.
Global collaboration is essential to address these gaps. #ClinicalTrials
Adjunctive therapies for BKPyVAN lack robust efficacy:
• IVIG: Limited support as an adjunct.
• Fluoroquinolones & cidofovir: Lack efficacy and carry significant toxicity.
Better therapeutic options are urgently needed. #NephrologyInnovation
• IVIG: Limited support as an adjunct.
• Fluoroquinolones & cidofovir: Lack efficacy and carry significant toxicity.
Better therapeutic options are urgently needed. #NephrologyInnovation
January 12, 2025 at 1:11 PM
Adjunctive therapies for BKPyVAN lack robust efficacy:
• IVIG: Limited support as an adjunct.
• Fluoroquinolones & cidofovir: Lack efficacy and carry significant toxicity.
Better therapeutic options are urgently needed. #NephrologyInnovation
• IVIG: Limited support as an adjunct.
• Fluoroquinolones & cidofovir: Lack efficacy and carry significant toxicity.
Better therapeutic options are urgently needed. #NephrologyInnovation
Diagnosis highlights:
• Gold standard: Kidney biopsy, but false negatives are common due to the focal nature of BKPyVAN.
• BKPyV DNAemia detected via qPCR serves as a key screening tool, but assay variability limits universal thresholds. #DiagnosisMatters
• Gold standard: Kidney biopsy, but false negatives are common due to the focal nature of BKPyVAN.
• BKPyV DNAemia detected via qPCR serves as a key screening tool, but assay variability limits universal thresholds. #DiagnosisMatters
January 12, 2025 at 1:11 PM
Diagnosis highlights:
• Gold standard: Kidney biopsy, but false negatives are common due to the focal nature of BKPyVAN.
• BKPyV DNAemia detected via qPCR serves as a key screening tool, but assay variability limits universal thresholds. #DiagnosisMatters
• Gold standard: Kidney biopsy, but false negatives are common due to the focal nature of BKPyVAN.
• BKPyV DNAemia detected via qPCR serves as a key screening tool, but assay variability limits universal thresholds. #DiagnosisMatters
